Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoGen

This article was originally published in The Gray Sheet

Executive Summary

Raises $12 mil. in private placement led by Invesco Private Capital. San Diego-based CryoGen will use the funds to conclude clinical research and begin commercialization of its FirstOption Uterine Cryoblation therapy system to treat abnormal uterine bleeding. The miniature, closed-cycle cryoablation device, which is designed to allow physicians to ablate tissue at extremely low temperatures, is currently being evaluated at 11 centers in the U.S. The financing, which will also support R&D for cardiac applications of the cryoblation technology, brings the development-stage firm's total venture capital funding to $25.5 mil

You may also be interested in...



CryoGen On Track For Second Quarter Endometrial Ablation PMA Submission

Cryogen plans to file data in support of a premarket approval application during the second quarter to expand labeling for the First Option intrauterine cryosurgical probe to include specific references to endometrial ablation as a treatment for dysfunctional uterine bleeding.

UK Grants First Worldwide Authorization For PfIzer/BioNTech COVID-19 Vaccine

The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

UsernamePublicRestriction

Register

PS100968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel